Cite
HARVARD Citation
Andtbacka, R. et al. (2019). Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. Journal for immunotherapy of cancer. 7 (1), p. . [Online].